


Amendments in the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-4. (canceled)

Claim 5. (currently amended): A pharmaceutical composition comprising one or more of ~~[[the]] compounds as claimed in claim 1 I,~~



I

wherein

A is (C₁-C₈)alkyl, (C₀-C₈)alkylenearyl; a 3- to 12-membered mono- or bicyclic ring which may contain one or more heteroatoms selected from the group consisting of N, O, and S, and the 3- to 12-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO₂, CF₃, OCF₃, CN, (C₁-C₆)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-(C₁-C₆)alkyl, S-(C₁-C₆)alkyl, and NHCO(C₁-C₆)alkyl;

X is a bond, C(R8)(R9), C(OR10)(R11), O, N(R12), S, SO, SO₂, or CO;

R8, R9, R10, R11, R12 are, independently of one another, H or (C₁-C₆)alkyl;

D is N, or C(R41);

E is N, or C(R42);

G is N, or C(R43);

L is N, or C(R44);

R1, R2, R3, R41, R42, R43, R44 are, independently of one another, H, F, Cl, Br, J, OH, CF₃, NO₂, CN, OCF₃, O-(C₁-C₆)alkyl, (C₁-C₄)alkoxyalkyl, S-(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₃-C₈)cycloalkyl, O-(C₃-C₈)cycloalkyl, (C₃-C₈)cycloalkenyl, O-(C₃-C₈)cycloalkenyl, (C₂-C₆)alkynyl, (C₀-C₈)alkylenearyl, -O-(C₀-C₈)alkylenearyl, S-aryl, N(R13)(R14), SO₂-CH₃, COOH, COO-(C₁-C₆)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO₂(R20), CO(R21), or a 5- to 7-membered heterocycle having 1-4 heteroatoms;

R13, R14 are, independently of one another, H, (C₁-C₆)alkyl, or R13 and R14, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH₂ group may be replaced by O or S;

R15, R16 are, independently of one another, H, (C₁-C₆)alkyl, or R15 and R16, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH₂ group may be replaced by O or S;

R17, R19 are, independently of one another, H or (C₁-C₆)alkyl;

R18, R20, R21 are, independently of one another, (C₁-C₆)alkyl, or aryl;

B is N(R24) or O;

R24 is H or (C₁-C₆)alkyl;

R5 is H or (C₁-C₆)alkyl;

W is N, or C(R25);

R25 is H, (C₁-C₆)alkyl, aryl, or a bond to Y;

T is N, or C(R26);

R26 is H, (C₁-C₆)alkyl, aryl, (C₀-C₈)alkylenearyl, or a bond to Y;

U is O, S, N(R27), -C(R30)=N-, or -N=C(R31);

R27, R30, R31 are, independently of one another, H, (C₁-C₆)alkyl, or a bond to Y;

Y is (C₁-C₈)alkylene, in which one or more carbons may be replaced by O, S, SO, SO₂, C(R32)(R33), CO, C(R34)(OR35), or N(R36);

R32, R33, R34, R35, R36 are, independently of one another, H, (C₁-C₆)alkyl, or aryl;

R6, R7 are, independently of one another, H, (C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, or R6 and Y or R6 and R7, together with the nitrogen atom to which they are bonded, form a 3- to 8-membered ring in which one or more carbons may be replaced by O, N, or S, and the 3- to 8-membered ring may carry further substituents such as (C₁-C₆)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-(C₁-C₆)alkyl, or NHCO(C₁-C₆)alkyl;

R37, R38, R39, R40 are, independently of one another, H or (C₁-C₆)alkyl; and the physiologically acceptable salts thereof;

one or more anorectic active substances; and a physiologically acceptable carrier.

Claims 6-7. (canceled)

Claim 8. (currently amended): [[The]] A method for the prophylaxis or treatment of obesity of claim 6, further comprising administering to a mammal in need thereof an effective amount of [[an]] the anorectic active substance of claim 5.

Claim 9. (currently amended): [[The]] A method for the prophylaxis or treatment of type II diabetes of claim 7, further comprising administering to a mammal in need thereof an effective amount of [[an]] the anorectic active substance of claim 5.

Claims 10-15. (canceled)